R
  • 773.714.0705
  • Home
  • About Us
  • Specialty
  • Activities
    • Live
    • Online
  • Outcomes & Toolkits
New User? Login
Certificate Use Certificate Code

Overview

Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer

SHARE WITH COLLEAGUE

Activity URL:

https://www.achlcme.org/detail/5025/Modeling-Center-of-Excellence-Practices-to-Improve-the-...

Click the"View Activity" button to view this activity.

View Activity

CME/CE is no longer available for this activity

Modeling Center of Excellence Practices to Improve the Care of Patients With Biomarker-Driven Thyroid Cancer or Non-Small-Cell Lung Cancer
Format
Interactive Practice Guide
Time to Complete
1.00 hr(s).
Release Date
January 31, 2024
Expires On
January 31, 2025

Biomarker testing is key to unlocking the potential of precision medicine. Are your molecular testing procedures optimized to guide treatment for your patients with advanced NSCLC or thyroid cancer?  

Assess your current practices, review the latest evidence and best practices shared by leaders in the field, and create a plan to optimize testing and treatment selection practices to ensure your patients are benefitting from the latest advancements in biomarker testing and precision medicine.  Different education pathways are available for thyroid cancer, NSCLC, and a focus on molecular pathology in both tumor types. Use these materials on your own or to facilitate scenario-based learning and action planning with your team to improve biomarker testing practices. 

This activity is intended for intended for oncologists, pathologists and the multidisciplinary team practicing in academic and community settings who treat patients with NSCLC or thyroid cancer.

The identification of targetable tumor-specific molecular alterations has grown rapidly, leading to the application of precision medicine in oncology. Recently, therapies targeting receptor tyrosine kinase RET (rearranged during transfection) gene alterations have been developed for the treatment of multiple malignancies, including NSCLC and thyroid cancers. Although testing for RET alterations is recommended, such testing is underutilized in clinical practice, leading to suboptimal treatment selection. Moreover, a wide variance among institutions has been found in the utilization of molecular testing procedures, stemming from several factors including delays in physician orders (vs reflex testing), collection of tissue samples that are adequate for biopsies but inadequate for molecular testing, and test turnaround time. 

Therefore, education on optimal molecular testing strategies and treatment selection, and development of strategies to overcome testing challenges, are vital for improving patient care. The promise of precision medicine rests in the collaborative team of pathologists and oncologists and the integration of molecular testing to optimize treatment of patients diagnosed with NSCLC or thyroid cancer. This program will provide practical guidance for improving clinical ability to follow guideline recommendations for identifying the most appropriate molecular tests, as well increasing proficiency in applying testing results to treatment selection.  In addition, through expert guidance, this program will aid you in developing strategies to overcome testing barriers and improve protocols and workflows to enhance clinical practices and improve patient outcomes.

• Develop improved models for early and effective biomarker testing 
• Identify appropriate patients and optimize treatment for RET-targeted therapy
• Develop strategies to mitigate challenges and barriers to optimizing RET testing for patients with NSCLC and thyroid cancer

Provided by The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

This activity is supported by an educational grant from Lilly.

Maria Arcila, MD
Attending Pathologist and Laboratory Director, Diagnostic Molecular Pathology
Medical Director, Molecular Hematopathology
Memorial Sloan Kettering Cancer Center
New York, NY

Marcia Brose, MD, PhD, FASCO
Director, Cancer Services
Vice Chair, Hematology and Medical Oncology
Co-Director Community Based Clinical Trials
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, PA

Lori Wirth, MD
Associate Professor
Harvard Medical School
Medical Director
Massachusetts General Hospital’s Center for Head and Neck Cancers
Boston, MA

Christine Bestvina, MD  (Content Reviewer)
Associate Professor 
Department of Medicine, Section of Hematology/Oncology 
University of Chicago Medicine 
Chicago, IL

The University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL) require that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any ineligible companies. All relevant financial relationships have been mitigated prior to this activity. 
The following financial relationships have been provided:

Maria Arcila, MD 
Consultant: AstraZeneca, Bristol-Myers Squibb, Janssen Global Services, and Roche Diagnostics
Advisory Board: Biocartis Global

Marcia Brose, MD, PhD, FASCO 
Consultant: Bayer, Eisai Co., Ltd., Exelixis, Inc., Lilly
Honorarium recipient: Eisai Co., Ltd. 

Lori Wirth, MD 
Consultant/Advisor: AbbVie, Bayer, Coherus, Eli Lilly, Eisai, EMD Serono, Exelixis, Genentech
Strategic Council Member: Galera Therapeutics
Scientific Advisory Committee: Ellipses 
Data and Safety Monitoring Committee (DSMC) Member: PDS Biotechnology

Christine Bestvina, MD 
Grants/Research Support: AstraZeneca, Bristol Myers Squibb
Consultant: AstraZeneca, Bristol Myers Squibb, CVS, Daiichi Sankyo, EMD Sereono, Gilead, Mirati, Novocure, Regeneron, Sanofi, Takeda, Tempus

Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Pralsetinib is not approved for the treatment of advanced/metastatic medullary thyroid cancer

University of Chicago staff members, ACHL staff members, and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).

This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. The University of Chicago and ACHL require the speaker to disclose that a product is not labeled for the use under discussion.

This activity will take approximately 60 minutes to complete. To receive credit, learners are required to complete the pretest, view the online activity, and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

For questions, contact McKenna Reinhard at mreinhard@achlcme.org. 

The University of Chicago Pritzker School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The University of Chicago Pritzker School of Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician assistants, nurse practitioners, and nurses may participate in this educational activity and earn a certificate of completion as AAPA, AANP, and ANCC accept AMA PRA Category 1 Credits™ through their reciprocity agreements.

McKenna Reinhard
mreinhard@achlcme.org
(773)714-0705 ext. 121
Related Activities
View All Activities

You are being redirected to another site.


footer-logo

308 S. Jefferson St.,
Suite 312,
Chicago, IL 60661

  • Phone: 773.714.0705
  • Fax: 773.714.0707
  • Home
  • Specialty
  • Sitemap
  • Privacy Policy
  • Contact Us
  • Follow us on Twitter
  • Like us on Facebook
  • Follow us on LinkedIn

Copyright © 2025 Academy for Continued Healthcare Learning. All Rights Reserved.

Processing...
×